Protease-activated T cell bispecific molecules

US11242390B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Peter Bruenker · Hittnau, CH
• Rebecca CROASDALE-WOOD · Penzberg, DE
• Christian Klein · Iffeldorf, DE
• Juergen Michael Schanzer · Traunstein, DE
• Kay-Gunnar Stubenrauch · Frauenfeld, CH
• Pablo Umana · Wollerau, CH
• Martina GEIGER · Obfelden, CH
• Eric Sullivan · Louisville, US
• Jigar Patel · London, GB

Key dates

• Filing date: Sep 21, 2018
• Grant date: Feb 8, 2022
• Expiry date: Sep 21, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.